Vis enkel innførsel

dc.contributor.authorChen, X
dc.contributor.authorZhu, Q
dc.contributor.authorLiu, Y
dc.contributor.authorLiu, P
dc.contributor.authorYin, Y
dc.contributor.authorGuo, R
dc.contributor.authorLu, K
dc.contributor.authorGu, Y
dc.contributor.authorLiu, L
dc.contributor.authorWang, J
dc.contributor.authorWang, Z
dc.contributor.authorRøe, Oluf Dimitri
dc.contributor.authorShu, Y
dc.contributor.authorZhu, L
dc.date.accessioned2015-11-24T13:04:33Z
dc.date.accessioned2015-12-04T10:12:54Z
dc.date.available2015-11-24T13:04:33Z
dc.date.available2015-12-04T10:12:54Z
dc.date.issued2014
dc.identifier.citationPLoS ONE 2014, 9(5)nb_NO
dc.identifier.issn1932-6203
dc.identifier.urihttp://hdl.handle.net/11250/2366943
dc.description.abstractBackground Icotinib hydrochloride is a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with preclinical and clinical activity in non-small cell lung cancer (NSCLC). This retrospective analysis was performed to assess the efficacy of icotinib on patients with non-small-cell lung cancer (NSCLC). Methods 82 consecutive patients treated with icotinib as first (n = 24) or second/third line (n = 58) treatment at three hospitals in Nanjing were enrolled into our retrospective research. The Response Evaluation Criteria in Solid Tumors (RECIST) was used to evaluate the tumor responses and the progression-free survival (PFS) and overall survival (OS) was evaluated by the Kaplan-Meier method. Results Median PFS was 4.0 months (95% CI 2.311–5.689). Median OS was 11.0 months (95% CI 8.537–13.463) in this cohort. Median PFS for first and second/third line were 7.0 months (95% CI 2.151–11.8) and 3.0 months (95% CI 1.042–4.958), respectively. Median OS for first and second/third line were 13.0 months (95% CI 10.305–15.695) and 10.0 months (95% CI 7.295–12.70), respectively. In patients with EGFR mutation (n = 19), icotinib significantly reduced the risk of progression (HR 0.36, 95% CI 0.18–0.70, p = 0.003) and death (HR 0.10, 95% CI 0.02–0.42, p = 0.002) compared with those EGFR status unknown (n = 63). The most common adverse events were acne-like rash (39.0%) and diarrhea (20.7%). Conclusions Icotinib is active in the treatment of patients with NSCLC both in first or second/third line, especially in those patients harbouring EGFR mutations, with an acceptable adverse event profile.nb_NO
dc.language.isoengnb_NO
dc.publisherPublic Library of Sciencenb_NO
dc.titleIcotinib is an active treatment of non-small-cell lung cancer: A retrospective studynb_NO
dc.typeJournal articlenb_NO
dc.typePeer revieweden_GB
dc.date.updated2015-11-24T13:04:33Z
dc.source.volume9nb_NO
dc.source.journalPLoS ONEnb_NO
dc.source.issue5nb_NO
dc.identifier.doi10.1371/journal.pone.0095897
dc.identifier.cristin1168506
dc.description.localcode© 2014 Chen et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.nb_NO


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel